Page 160 - Q26 - 0
P. 160
¥ÿ≈æ“À
United Nations Development Programme (UNDP). Good Practice Guide:
Improving Access To Treatment By Utilizing Public Health Flexibilities
In The WTO TRIPS Agreement, 2010.
Said, Mohamad El, and Amy Kapczynski. çAccess to Medicines: The Role
of Intellectual Property Law and Policy.é†Working Paper Prepared for
the Third Meeting of the Technical Advisory Group of the Global
Commission on HIV and the Law, 2011.
Sawicka, Monika, and Ron A. Bouchard. çEmpirical Analysis of Canadian Drug
Approval Data 2001-2008: Are Pharmaceutical Players ùDoing More with
Lessû?.é†MCGILL JOURNAL OF LAW AND HEALTH / REVUE DE
DROIT ET SANTÉ DE MCGILL†3 (2009): 85.
Shadlen, Kenneth C., and S. Guennif.†Intellectual Property, Pharmaceuticals
and Public Health: Access to Drugs in Developing Countries. Edward
Elgar Publishing, 2011.
Sooksriwong, Cha-oncin. çMedicine Prices in Thailand: A Result of No
Medicine Pricing Policy.é†Southern Med Review†2, no. 2 (2009): 13.
Tunsarawut, Sinfah. çEvergreened Patents Cause Unwarranted High Drug Prices,
Hinder Growth Of Local Producers -NGOs, Thai Producers Claim.é
Intellectual Property Watch, 2018. http://www.ip-watch.org/2018/05/07/
evergreened-patents-cause-unwarranted-high-drug-prices-hinder-growth-
local-producers-ngos-thai-producers-claim/.
World Health Organisation.†Commission on Intellectual Property Rights,
Innovation. and Public Health, Public Health, Innovation and Intellectual
¡°√“§¡ - ‡¡…“¬π ÚıˆÛ 149
